No quarterly revenue total was found in BIOATLA, INC.'s SEC filings.
Bioatla, Inc. (BCAB) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $1.5 million in cash and investments and $5.9 million in total debt.
Revenue
—
Net income
$452,000
+102.4% vs year-ago quarter
Operating cash flow
$-419,000
+97.0% vs year-ago quarter
Free cash flow
—
EPS
$0.27
+101.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.66M
-97.2% vs year-ago quarter
Net cash
$-4.32M
Q2 FY2026
Operating margin
-43237.0%
TTM
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCAB (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1826892
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | $227,000 | -$9.3M | -$9.3M | -$13.8M | -$18.6M |
| Net income | $452,000 | -$6.3M | -$9.8M | -$15.8M | -$18.7M |
| Diluted EPS | $0.27 | -$4.22 | -$0.16 | -$0.27 | -$15.99 |
| Operating cash flow | -$419,000 | -$5.3M | -$7.9M | -$9.9M | -$14.1M |
| Total assets | $9.5M | $8.6M | $13.8M | $15.9M | $27.1M |
| Total liabilities | $45.7M | $45.9M | $50.0M | $47.1M | $43.9M |
| Stockholders' equity | -$36.2M | -$37.3M | -$36.2M | -$31.2M | -$16.7M |
| Cash and investments | $1.5M | $2.0M | $7.1M | $8.3M | $18.2M |
| Total debt | $5.9M | $6.1M | $6.2M | $6.2M | $6.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Agreement ended, Unregistered share sale
|
Oct 20, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 26, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 16, 2026 | Jul 16, 2026 |
| ARS | Annual report to shareholders | Jun 3, 2026 | Dec 31, 2025 |
All 509 Bioatla, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.